Spoken Alpha
Intercure Ltd.
Intercure Ltd is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $53.1M market cap.
Most recent earnings call: Q4 FY22 on Apr 4, 2023.
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks INCR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for INCR.
$ curl https://api.spokenalpha.com/v1/companies/INCRFAQ
Spoken Alpha indexes INCR's earnings call transcripts at https://spokenalpha.com/companies/INCR. Each call links to attributed speakers and parsed analyst Q&A.
Intercure Ltd. (INCR) held its most recent earnings call on 2023-04-04, covering fiscal Q4 2022.
Intercure Ltd. (INCR) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $4.07 | $3.16 | +28.9% | +5.7% | +6.8% |
| Q4 FY2022 | $3.89 | $3.00 | +29.7% | +4.2% | +3.4% |
| Q3 FY2022 | $3.75 | $3.00 | +24.9% | -0.1% | +0.9% |
| Q2 FY2022 | $3.82 | $2.94 | +30.1% | +8.8% | +10.9% |
| Q1 FY2021 | $4.09 | $3.14 | +30.3% | +4.3% | +2.0% |
| Q4 FY2021 |
| $4.09 |
| $3.16 |
| +29.3% |
| -0.8% |
| -1.4% |
| Q3 FY2021 | $4.17 | $3.29 | +26.8% | +0.4% | -1.3% |
| Q2 FY2021 | $4.06 | $3.12 | +30.1% | +9.0% | +11.3% |
| Q1 FY2020 | $4.36 | $3.29 | +32.6% | +3.1% | +3.4% |
| Q4 FY2020 | $4.28 | $3.21 | +33.3% | +1.7% | +1.6% |